Effects of interleukin-1 antagonism on cortisol levels in individuals with obesity: a randomized clinical trial

BACKGROUND: Anti-inflammatory treatment with interleukin-1 (IL-1) antagonism decreases both cortisol and adrenocorticotropin hormone (ACTH) levels in individuals with obesity in short term. However, it remains unknown whether these effects persist upon prolonged treatment. METHODS: In this double-bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebrahimi, Fahim, Urwyler, Sandrine A, Schuetz, Philipp, Mueller, Beat, Bernasconi, Luca, Neyer, Peter, Donath, Marc Y, Christ-Crain, Mirjam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547405/
https://www.ncbi.nlm.nih.gov/pubmed/31042669
http://dx.doi.org/10.1530/EC-19-0201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547405/
https://www.ncbi.nlm.nih.gov/pubmed/31042669
http://dx.doi.org/10.1530/EC-19-0201

Ejemplares similares